ZIVO Bioscience (ZIVO) Competitors $18.22 +0.21 (+1.17%) As of 08/13/2025 01:13 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ZIVO vs. CRGX, NLTX, IPHA, ENGN, AVTE, MDWD, GNFT, VYGR, VTYX, and DMACShould you be buying ZIVO Bioscience stock or one of its competitors? The main competitors of ZIVO Bioscience include CARGO Therapeutics (CRGX), Neoleukin Therapeutics (NLTX), Innate Pharma (IPHA), enGene (ENGN), Aerovate Therapeutics (AVTE), MediWound (MDWD), GENFIT (GNFT), Voyager Therapeutics (VYGR), Ventyx Biosciences (VTYX), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry. ZIVO Bioscience vs. Its Competitors CARGO Therapeutics Neoleukin Therapeutics Innate Pharma enGene Aerovate Therapeutics MediWound GENFIT Voyager Therapeutics Ventyx Biosciences DiaMedica Therapeutics CARGO Therapeutics (NASDAQ:CRGX) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk. Which has more risk & volatility, CRGX or ZIVO? CARGO Therapeutics has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, ZIVO Bioscience has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500. Is CRGX or ZIVO more profitable? ZIVO Bioscience's return on equity of 0.00% beat CARGO Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CARGO TherapeuticsN/A -43.21% -37.26% ZIVO Bioscience N/A N/A -2,240.92% Do analysts prefer CRGX or ZIVO? CARGO Therapeutics currently has a consensus price target of $15.40, suggesting a potential upside of 245.29%. Given CARGO Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe CARGO Therapeutics is more favorable than ZIVO Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CARGO Therapeutics 1 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.86ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings and valuation, CRGX or ZIVO? ZIVO Bioscience has higher revenue and earnings than CARGO Therapeutics. ZIVO Bioscience is trading at a lower price-to-earnings ratio than CARGO Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCARGO TherapeuticsN/AN/A-$167.50M-$4.64-0.96ZIVO Bioscience$15.85K4,387.74-$7.78M-$4.93-3.70 Do insiders & institutionals have more ownership in CRGX or ZIVO? 93.2% of CARGO Therapeutics shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 2.9% of CARGO Therapeutics shares are owned by company insiders. Comparatively, 48.9% of ZIVO Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media prefer CRGX or ZIVO? In the previous week, CARGO Therapeutics had 2 more articles in the media than ZIVO Bioscience. MarketBeat recorded 2 mentions for CARGO Therapeutics and 0 mentions for ZIVO Bioscience. CARGO Therapeutics' average media sentiment score of 0.62 beat ZIVO Bioscience's score of 0.00 indicating that CARGO Therapeutics is being referred to more favorably in the media. Company Overall Sentiment CARGO Therapeutics Positive ZIVO Bioscience Neutral SummaryCARGO Therapeutics beats ZIVO Bioscience on 9 of the 13 factors compared between the two stocks. Get ZIVO Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ZIVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZIVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZIVO vs. The Competition Export to ExcelMetricZIVO BioscienceBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$69.55M$282.85M$5.61B$9.84BDividend YieldN/AN/A4.61%4.07%P/E Ratio-3.73N/A30.2925.74Price / Sales4,387.74570.35463.41115.83Price / CashN/A22.4438.2159.48Price / Book-22.499.418.826.15Net Income-$7.78M-$115.81M$3.25B$265.06M7 Day Performance25.74%2.63%3.70%2.60%1 Month Performance37.20%-0.34%5.84%2.83%1 Year Performance167.94%-2.92%29.92%25.58% ZIVO Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZIVOZIVO Bioscience0.242 of 5 stars$18.22+1.2%N/A+112.4%$69.55M$15.85K-3.7310CRGXCARGO Therapeutics2.1101 of 5 stars$4.47-0.3%$15.40+244.9%-73.0%$205.88MN/A-0.97116Positive NewsNLTXNeoleukin TherapeuticsN/A$21.72-0.3%N/A-38.2%$204.13MN/A-6.9890News CoverageIPHAInnate Pharma2.2316 of 5 stars$2.18+3.3%$11.00+404.6%-0.5%$200.95M$21.77M0.00220Short Interest ↑Gap UpENGNenGene3.462 of 5 stars$3.90+2.1%$23.29+497.1%-33.8%$200.26MN/A-2.3831Short Interest ↓AVTEAerovate TherapeuticsN/A$6.89-4.2%N/A-87.8%$199.71MN/A-2.3020High Trading VolumeMDWDMediWound1.5584 of 5 stars$18.24-0.7%$32.25+76.8%+6.3%$197.14M$19.21M-8.7380News CoverageEarnings ReportGNFTGENFIT2.1445 of 5 stars$3.94+3.8%$13.00+230.4%+3.0%$196.75M$76.77M0.00120VYGRVoyager Therapeutics3.6972 of 5 stars$3.56+10.8%$13.39+276.4%-42.5%$195.07M$80M-2.41100VTYXVentyx Biosciences2.6302 of 5 stars$2.70-0.7%$10.00+270.1%+57.1%$193.91MN/A-1.5630DMACDiaMedica Therapeutics1.7678 of 5 stars$4.51+3.4%$10.75+138.4%+72.7%$193.17MN/A-7.0420Earnings ReportShort Interest ↑ Related Companies and Tools Related Companies CRGX Alternatives NLTX Alternatives IPHA Alternatives ENGN Alternatives AVTE Alternatives MDWD Alternatives GNFT Alternatives VYGR Alternatives VTYX Alternatives DMAC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZIVO) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZIVO Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZIVO Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access